Northwestern University and collaborators reported progress toward implantable “living pharmacies,” engineering cells encapsulated in a wireless, fully implantable device designed to continuously produce multiple medicines inside the body. The study describes the HOBIT platform, which integrates engineered cells with oxygen-generating bioelectronics to overcome local oxygen limits that otherwise kill implanted therapeutic cells. In separate work highlighted by the same platform direction, the researchers engineered cells to simultaneously produce three biologics—an anti-HIV antibody, a GLP-1-like peptide, and leptin—demonstrating stable co-delivery in small animal models for weeks. The advance targets a core translational barrier for cell-based drug factories: maintaining viability and output in vivo without external dosing or patient carrying devices.